TARIS Biomedical LLC
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From TARIS Biomedical LLC
Fourteen drugs are in clinical development for overactive bladder, most of which are early-to-mid stage and oral.
Private Company Edition: Flagship ends 2017 with its biggest life science fund yet totaling $618m. Also, December sees a year-end surge in VC deals, including a $100m Series B round for Allakos.
The Bone, Reproductive and Urologic Drugs Advisory Committee will consider endpoints, clinical trial designs and other issues related to development in the disease.
According to a new analysis from Datamonitor Healthcare, the volume of deals in the CNS space has fallen since 2012 but the overall value of alliances is increasing, particularly when it comes to up-front payments for potential Alzheimer's therapies.
- Medical Devices
- Implantable Devices
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.